IMV

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapy more effective and widely available for people with cancer and other serious diseases. IMV's proprietary drug development platform provides patented delivery formulations that enable controlled and prolonged exposure of antigens to the immune system. The lead candidate product, DPX-Survivac, is currently undergoing several late-stage clinical trials for ovarian cancer and evaluations with other innovative immunotherapeutic agents.